Central Nervous System

Format: 2017-02-22
Format: 2017-02-22
January 12, 2017 | 73 Pages | SKU: IRTNTR11520

Overview of the myasthenia gravis drugs market

Extensive research carried out by the market research analysts at Technavio has shown that the global myasthenia gravis drugs market will witness impressive growth and post a staggering CAGR of more than 13% over the forecast period. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies. For instance, Soliris (eculizumab) is one such drug that is currently in Phase III development stage. The drug acts by restricting the disease cells from affecting the immune system. Soliris (eculizumab) is anticipated to receive approval by the end of 2017 or in early 2018 in the US. Some of the other monoclonal antibodies in the pipeline include Novartis' CFZ-533 and GlaxoSmithKline's Benlysta. With several monoclonal antibody-based drugs in the pipeline, the market for myasthenia gravis drugs will have a positive outlook in the coming years.

One of the recent trends gaining traction in the market is the growing number of strategic acquisitions in the market. Several vendors are looking to expand their product portfolio and market presence by pursuing inorganic growth strategies such as acquisitions. Such growth strategies allow companies to reduce R&D costs and quickly establish a presence in the


December 30, 2016 | 128 Pages | SKU: IRTNTR11316

Overview of the global protein therapeutics market

Market research analysts at Technavio predict that the global protein therapeutics market will grow steadily during the next four years and post a CAGR of almost 8% by 2021. This market research analysis identifies the increased demand for monoclonal antibodies (mAbs) as one of the primary growth factors for this market. mAbs accounts for a major share of protein therapeutics. The increasing usage of mAbs in various therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy will drive the growth of the market. Additionally, mAbs are also used in the formulation of biopharmaceutical drugs for the treatment of different diseases including cancer and ulcerative colitis which will also aid in the market’s growth in the coming years.

This market research and analysis estimates that in terms of geographical regions, the Americas will be the major revenue contributor to the market throughout the forecast period. Factors such as the increase in uptake of the existing protein therapeutics and the rise in approvals for certain formulations that will induce more vendors to conduct R&D activities and enter the market, will boost the market’s growth prospects in this region.  

Competitive landscape and key vendors

The market is highly competitive and consists of numerous small and large-scale vendors who operate at a local or global scale. To enhance their global reach and increase revenue shares, vendors have started forming strategic alliances to manufacture and market drugs. Companies engaged in manufacturing and marketing protein therapeutics that can effectively treat various disorders will gain a competitive edge over the other vendors in the market. The market’s growth


December 29, 2016 | 77 Pages | SKU: IRTNTR11320

Overview of the global chemotherapy-induced nausea and vomiting (CINV) drugs market

Market research analysts at Technavio predict that the global CINV drugs market will grow steadily during the next four years and post a CAGR of almost 6% by 2021. This market research analysis identifies the growing preference of chemotherapy in the developing countries across the globe as one of the primary growth factors for the chemotherapy-induced nausea and vomiting drugs market. Though the use of chemotherapy drugs in combination with other therapies will drive the demand in the developed countries, the coming years will still witness a decline in the preference for chemotherapy drugs in these regions. However, the increased preference toward chemotherapy for the treatment of cancer in the developing countries such as China and India will drive market growth since the demand for targeted therapies is still in the nascent phase in these countries. This will drive the demand for CINV drugs, consequently fuelling market growth.

To enhance their product portfolio and establish their market presence vendors will start following inorganic growth strategies such as acquisitions and alliances, which will allow market players to reduce their R&D costs and quickly penetrate into the market. For instance, Helsinn and Purdue Pharma Canada entered into an exclusive agreement for the distribution and licensing of the CINV drug Akynzeo. This enabled Helsinn to retain the clinical development, manufacturing, and commercialization of Akynzeo, whereas Purdue Pharma Canada gained the right to register, promote, and commercialize Akynzeo in Canada.

Competitive landscape and key vendors

The market is characterized by the presence of a considerable number of vendors and appears to be highly fragmented. Vendors


December 13, 2016 | 65 Pages | SKU: IRTNTR11105

Overview of the global Pompe disease treatment market

Market research analysts at Technavio predict that the global Pompe disease treatment market will grow steadily during the next four years and post a CAGR of almost 12% by 2020. This market research analysis identifies the availability of reimbursement policies for the treatment Pompe disease as one of the primary factors that will have a positive impact on the growth of this market. It has been observed that the treatment of Pompe disease costs around USD 100,000 to USD 300,000 for an individual every year, making it difficult for individuals to continue with the treatment for a long period. However, financial support from various organizations such as the Canadian Association of Pompe, Acid Maltase Deficiency Association, and International Pompe Association enables patients continue their treatment, which will drive the growth of the market. Additionally, initiatives from the governments of countries such as Sweden, the Netherlands, and South Korea that focus on approving guidelines for the reimbursement of individuals undergoing enzyme replacement therapy (ERT) will also bolster the growth of the market in the next four years.

One of the major trends that will gain traction in the Pompe treatment market is the emergence of immunotherapy for Pompe disease. Immunotherapy enhances the powers of the immune system and aids in fighting various respiratory, infectious, and autoimmune disorders. Advances in preventing Immunoglobin (IgG) production have shown a significant effect in both pre-clinical and clinical studies. This will result in the increased adoption of drugs such as mycophenolate mofetil, cyclophosphamide, and methotrexate for the prevention of responses to ERT as they have


September 22, 2016 | 147 Pages | SKU: IRTNTR10192

Overview of the central nervous system (CNS) disorders therapeutics market

The market research analyst at Technavio predicts that the global central nervous system (CNS) disorders therapeutics market will grow steadily and post a CAGR of approximately 3% by 2020. One of the factors contributing to the growth of the market will be the allotment of special regulatory designations for CNS disorders. The designations assigned to drugs by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) help in the faster entry of these drugs into the market for the treatment of serious conditions. Currently, in the US, orphan drugs are offered incentives such as tax credits for clinical testing, exemption from prescription fees, and market exclusivity for seven years. Recently, the US FDA granted a breakthrough therapy designation for Roche’s investigational drug, Ocrelizumab, for the treatment of primary progressive multiple sclerosis.

One of the recent trends in the market is the increasing focus on regenerative therapies for CNS disorders. These therapies help in the healing process by replacement or regeneration of human cells, tissues or organs, and various regenerative therapies, including stem cells, growth factors, and the use of a matrix such as fibrin, collagen, and hyaluronic acid. Consequently, various vendors have strted engaging in the development of regenerative medicines with the help of advancements in technology and product innovation.

Competitive landscape and key vendors

In this market, many existing and emerging companies have started launching grounding breaking products and medicines to cure certain ailments. Major vendors are


August 01, 2016 | 94 Pages | SKU: IRTNTR8628

Outlook of the global pain management drugs market

Technavio’s market research analyst predicts the global pain management drugs market to grow moderately at a CAGR of around 4% until 2020. The launch of several innovative combination therapies during the forecast period will help to foster the prospects for market growth. Also, factors such as the recent increase in older population and chronic conditions will play a significant role in the growth and development of this market.

The recent rise in the awareness of pain management drugs will help in the growth of this market until 2020. The acceptability of pain management drugs will rise during the forecast period due to increasing public awareness about the availability of treatments. This increase in the general awareness will lead to an increase in research funding for clinical and support services.

Segmentation by drug class and analysis of the pain management drugs market

  • Opioids
  • NSAIDs

In 2015, the Opioids segment dominated this market and accounted for more than 49% of the total market share. The presence of late-stage pipeline molecules is expected to drive the market despite the loss of patent exclusivity on major drugs.

Geographical segmentation of the pain management drugs market

  • Americas
  • APAC
  • Europe

In 2015, the Americas was the largest market for pain management drugs as it accounted for a market share of more than 52%. The market in the Americas is expected to grow at a slow pace during the forecast period due to intense competition from generics. However, the growth of this market in the Americas can be attributed to the presence of a strong pipeline and favorable regulatory scenario.

Competitive


Pages